COPD Survey: PBAC Breztri Aerosphere ® |
PBAC – Breztri Aerosphere ® submission for funding on the PBS
AstraZenca Pty Ltd have made an application to list Breztri Aerosphere ® on the Pharmaceutical Benefits Scheme (PBS). AstraZenca have also made a concurrent application to the Therapeutic Goods Administration to register Brextri Aerosphere ® for use as a medicine in Australia.
Brextri Aerosphere ® is a triple therapy delivering 3 medicines, or active ingredients, (budesonide, formoterol fumarate dihydrate and glycopyrronium) via a pressure metered dose inhaler (“puffer”) device for people with moderate to severe chronic obstructive pulmonary disease (COPD). The device contains 120 doses and is to be used twice a day for maintenance of COPD.
This short survey seeks your views on patient and carer perspectives of the new treatment and the risk, benefits and opportunities it may provide.
This survey is for all patients experiencing COPD, their family and carers. You can complete this survey despite not using Breztri Aerosphere ® or another triple therapy.
We know from previous surveys completed by patients with COPD and their carers that:
99% of people support the listing on the PBS of additional treatment choices for people experiencing moderate to severe COPD.
90% of people ranked additional treatment choices as very important (the highest rank).
89% of people believe that having all three medicines in one device would help them take doses regularly and at the same time.
86% of people believed that a therapy delivered by an MDI device (“puffer”) is easier to use than a dry powder inhaler, and
98% of people said that having all three medicines in one device would be cost effective and environmentally sustainable.
This information is relevant to the current application and we will use it again. Therefore, this survey is shorter and focusses on the specific outcomes and side effects of Breztri Aerosphere ®.
The information gathered in this survey will be used to develop the Lung Foundation Australia submission to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding this therapy.
Brextri Aerosphere ® is a triple therapy delivering 3 medicines, or active ingredients, (budesonide, formoterol fumarate dihydrate and glycopyrronium) via a pressure metered dose inhaler (“puffer”) device for people with moderate to severe chronic obstructive pulmonary disease (COPD). The device contains 120 doses and is to be used twice a day for maintenance of COPD.
This short survey seeks your views on patient and carer perspectives of the new treatment and the risk, benefits and opportunities it may provide.
This survey is for all patients experiencing COPD, their family and carers. You can complete this survey despite not using Breztri Aerosphere ® or another triple therapy.
We know from previous surveys completed by patients with COPD and their carers that:
99% of people support the listing on the PBS of additional treatment choices for people experiencing moderate to severe COPD.
90% of people ranked additional treatment choices as very important (the highest rank).
89% of people believe that having all three medicines in one device would help them take doses regularly and at the same time.
86% of people believed that a therapy delivered by an MDI device (“puffer”) is easier to use than a dry powder inhaler, and
98% of people said that having all three medicines in one device would be cost effective and environmentally sustainable.
This information is relevant to the current application and we will use it again. Therefore, this survey is shorter and focusses on the specific outcomes and side effects of Breztri Aerosphere ®.
The information gathered in this survey will be used to develop the Lung Foundation Australia submission to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding this therapy.